Pfizer's Lung Cancer Drug Shows Record-Breaking Results and Billion-Dollar Potential
Pfizer's drug Lorbrena has shown promising long-term results in a late-stage trial for advanced non-small cell lung cancer with the ALK mutation, potentially establishing it as the new standard treatment. The drug significantly extended progression-free survival and reduced brain metastases compared to Pfizer's older drug Xalkori. The findings will be presented at the American Society of Clinical Oncology annual meeting.